1142223-08-2Relevant academic research and scientific papers
Design and Synthesis of Novel, Selective GPR40 AgoPAMs
Plummer, Christopher W.,Clements, Matthew J.,Chen, Helen,Rajagopalan, Murali,Josien, Hubert,Hagmann, William K.,Miller, Michael,Trujillo, Maria E.,Kirkland, Melissa,Kosinski, Daniel,Mane, Joel,Pachanski, Michele,Cheewatrakoolpong, Boonlert,Nolting, Andrew F.,Orr, Robert,Christensen, Melodie,Campeau, Louis-Charles,Wright, Michael J.,Bugianesi, Randal,Souza, Sarah,Zhang, Xiaoping,Di Salvo, Jerry,Weinglass, Adam B.,Tschirret-Guth, Richard,Nargund, Ravi,Howard, Andrew D.,Colletti, Steven L.
supporting information, p. 221 - 226 (2017/03/08)
GPR40 is a G-protein-coupled receptor expressed primarily in pancreatic islets and intestinal L-cells that has been a target of significant recent therapeutic interest for type II diabetes. Activation of GPR40 by partial agonists elicits insulin secretion
ANTIDIABETIC BICYCLIC COMPOUNDS
-
Page/Page column 105, (2014/09/03)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
Discovery of AM-1638: A potent and orally bioavailable GPR40/FFA1 full agonist
Brown, Sean P.,Dransfield, Paul J.,Vimolratana, Marc,Jiao, Xianyun,Zhu, Liusheng,Pattaropong, Vatee,Sun, Ying,Liu, Jinqian,Luo, Jian,Zhang, Jane,Wong, Simon,Zhuang, Run,Guo, Qi,Li, Frank,Medina, Julio C.,Swaminath, Gayathri,Lin, Daniel C.-H.,Houze, Jonathan B.
, p. 726 - 730 (2012/10/30)
GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels. A potent, orally bioavailable small molecule GPR40 agonist
